If you or your loved would like to learn more about any of the following clinical research studies, please contact us and one of our study coordinators will be in touch with you.
ANAVEX2-73 is a new small molecule that has been shown in previous research studies to improve mental activities that are involved in learning, remembering and using general daily knowledge. These results may indicate that ANAVEX2-73 has protective properties on the brain neurons that are usually damaged in Alzheimer’s disease.
NeuroCentrix provides access to clinical trials and potential new treatments for individuals with Alzheimer’s disease and Major Depression Disorder
© 2020 NeuroCentrix | Privacy Statement | Terms & Condtions
NeuroCentrix invites you to learn more about a Clinical Research Trial involving the use of a new investigational medication.